This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition

Bridger Management disclosed on Feb 17, 2026 that it fully liquidated its Masimo position, selling 47,841 shares and cutting the quarter-end holding by $7.06M (previously ~3.8% of the fund). Weeks after the exit Masimo agreed to a ~$180/share acquisition (~$9.9B), which subsequently drove the stock up ~34%; Masimo traded at $178.24 on Friday with a $9.6B market cap, TTM revenue $1.5B and TTM net loss $207.7M. The trade highlights portfolio timing risk and a tilt toward large-cap, cash-generating names in Bridger’s holdings, reducing exposure to event-driven upside.

Analysis

Bridger’s exit highlights a broader portfolio construction choice: prioritizing large-cap cash generators over idiosyncratic, event-driven healthcare names reduces headline volatility but also forfeits convex payoffs that arise from M&A, regulatory reversals, or product cycle inflections. That trade-off is non-linear — a 1-2% position in a mid-cap medtech can produce multi-turn outcomes from a single strategic event while only nudging multi-strategy volatility by cents on the dollar; funds prioritizing AUM stability will systematically under-sample that optionality.

From a competitive-dynamics standpoint, supply-chain and OEM partnership exposures matter more than headline end-markets. Firms that embed signal-extraction IP into broader hospital automation platforms create recurring revenue hooks for EMR vendors and device OEMs, shifting margin capture away from distributors and toward platform owners over 12–36 months. Adjacency winners include companies that can cross-sell into hospital IT stacks; losers are commodity sensor suppliers whose bargaining power shrinks as suites consolidate.

Key risks and catalysts: near-term price moves are driven by event-specific information flow (deal process, regulator signals, large OEM agreements) and can flip within days; medium-term performance hinges on reimbursement and adoption in hospital capital budgets over 6–18 months; long-term value depends on integration of sensing IP into platforms and protection of core patents over multiple years. A disciplined way to retain upside is size-constrained, optionality-led exposure rather than outright equity stakes that force binary sell decisions when liquidity or style constraints bite.

Key Decisions for Investors

• Buy convexity, not delta: initiate a small long-dated call-spread on MASI (6–12 month tenor). Example structure: long 10–12% OTM call, short 35–45% OTM call, position size 0.25–0.5% of portfolio; max loss = premium, target 3x–8x payoff if a strategic catalyst re-rates the name.
• Merger-arb conditional: if credible independent bid-level paperwork appears, allocate to a merger-arb long at spread ≤3% with regulatory checklists; otherwise require ≥6% spread to compensate for anti-trust/timing risk. Size to 0.5–1.0% AUM and hedge macro with a 1:1 short S&P futures notional to neutralize beta during litigation/approval window.
• Pair trade to harvest carry: go long MS (or AMZN) for 3–12 months as low-vol core and short a healthcare equipment ETF (or a direct competitor with weaker product integration) to tilt exposure toward durable cash flow while keeping event convexity via options. Target net drawdown limit 3% and rebalance monthly.
• Risk control: cap any event-driven exposure to single-stock deltas at 1% AUM, set time-stop of 12 months for option trades, and trim to half size on any 15% adverse move. Re-assess on catalyst delivery (earnings, OEM deals, regulatory notices).